Drug Trial Radar · NCT06512584
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Sep 3, 2024
Primary completion
Sep 28, 2026
Study completion Mar 15, 2027
Sponsor
- Lead sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are: * How effective is PJ009 in treating short bowel syndrome? * Is PJ009 safe in these patients? Researchers will compare PJ009 to a placebo (a look-alike substance that contains no drug) to see if PJ009 works to treat SBS. Participants will * Receive daily subcutaneous injections of PJ009 or placebo according to weight for 24 weeks, and then the participants receive placebo will be switched to receive PJ009 for another 12 weeks, while participants receive PJ009 continued the same treatment until the end of 36 weeks, * Visit the clinic at the end of week 1(w1), w2, w4, w8, w12, w16, w20, w24, w30 and w36 for assessment, * Keep a diary of the amount of their parenteral nutrition/ intravenous fluids (PN/IV), enteral nutrition and urine volume.
Conditions
- Short Bowel Syndrome
Interventions
PJ009Drug
subcutaneous injections, 0.05 mg/kg once daily
PJ009 PlaceboDrug
subcutaneous injections, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of respondersTime frame: Week 20 to 24 of treatment period
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
Chongqing General Hospital
Chongqing, Chongqing Municipality, China
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
The Third Xiangya Hospital of Central South University
Changsha, Hu'Nan, China
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.